UNITEDHEALTH GROUP INC
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
5. Short-Term Borrowings and Long-Term Debt
- Short-Term Borrowings and Long-Term Debt
In March 2024, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
| (in millions, except percentages) | Par Value |
|---|---|
| 4.600% notes due April 2027 | $500 |
| 4.700% notes due April 2029 | 400 |
| 4.900% notes due April 2031 | 1,000 |
| 5.000% notes due April 2034 | 1,250 |
| 5.375% Notes due April 2054 | 1,750 |
| 5.500% Notes due April 2064 | 1,100 |
In July 2024, the Company issued $12.0 billion of senior unsecured notes consisting of the following:
| (in millions, except percentages) | Par Value |
|---|---|
| Floating rate notes due July 2026 | $500 |
| 4.750% notes due July 2026 | 650 |
| 4.800% notes due January 2030 | 1,250 |
| 4.950% notes due January 2032 | 1,500 |
| 5.150% notes due July 2034 | 2,000 |
| 5.500% notes due July 2044 | 1,500 |
| 5.625% notes due July 2054 | 2,750 |
| 5.750% notes due July 2064 | 1,850 |
As of September 30, 2024, the Company had $1.2 billion of commercial paper outstanding, with a weighted-average annual interest rate of 5.4%.
In May 2024, the Company entered into an additional $3 billion 364-day revolving bank credit facility and a $5 billion 364-day delayed draw term loan. The $5 billion 364-day delayed draw term loan was terminated in September 2024. As of September 30, 2024 no amount had been drawn on any of the bank credit facilities.
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.